clopidogrel has been researched along with Angiogenesis, Pathologic in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T | 1 |
Bosmans, JM; Claeys, MJ; Michiels, JJ; Van Der Goten, P; Van der Planken, MG; Vertessen, F; Vrints, CJ; Wuyts, FL | 1 |
Cazenave, JP; Herbert, JM; Klein-Soyer, C; Maffrand, JP | 1 |
Bergerat, JP; Cazenave, JP; CĂ©raline, J; Chenard, MP; Deplanque, G; Klein-Soyer, C; Mah-Becherel, MC | 1 |
1 trial(s) available for clopidogrel and Angiogenesis, Pathologic
Article | Year |
---|---|
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Creatine Kinase; Creatine Kinase, MB Form; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Logistic Models; Male; Middle Aged; Neovascularization, Pathologic; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Recurrence; Stents; Survival Rate; Thrombosis; Ticlopidine; Troponin T | 2005 |
3 other study(ies) available for clopidogrel and Angiogenesis, Pathologic
Article | Year |
---|---|
Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation.
Topics: Animals; Antigens; Aspirin; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Disease Models, Animal; Endothelium; Fibrinolytic Agents; Male; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Nerve Tissue Proteins; Pericytes; Proteoglycans; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Ticlopidine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
SR 25989 inhibits healing of a mechanical wound of confluent human saphenous vein endothelial cells which is modulated by standard heparin and growth factors.
Topics: Cell Division; Cells, Cultured; Clopidogrel; Culture Media; Endothelium, Vascular; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Heparin; Humans; Neovascularization, Pathologic; Platelet Aggregation Inhibitors; Ticlopidine; Wound Healing | 1994 |
Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Cell Division; Clopidogrel; Disease Models, Animal; Foot; Gene Expression Regulation; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Microcirculation; Neoplasm Metastasis; Neoplasms, Experimental; Neovascularization, Pathologic; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Skin Neoplasms; Thrombospondin 1; Ticlopidine; Tumor Cells, Cultured | 2002 |